CD22 and acute lymphoblastic leukemia: Other pre-clinical work that has been under development includes CAR-T products targeting three antigens in B-ALL (CD19, CD20, and CD22), which have shown anti-leukemic efficacy in cell lines, primary patient samples, and animal models [65].